文献速递骨软组织肉瘤与黑色素瘤

转移性横纹肌肉瘤:欧洲儿童软组织肉瘤研究组MTS 2008研究结果及与同期BERNIE研究的汇总分析

Metastatic Rhabdomyosarcoma: Results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study.
PubMed 文献 · J Clin Oncol · 2022-06-16

MTS 2008研究纳入270例转移性横纹肌肉瘤患者,接受四周期IVA联合多柔比星、五周期IVA及12周期维持化疗,中位随访50.3个月,3年无事件生存率为34.9%、总生存率为47.9%。与BERNIE研究汇总的372例患者中位随访55.2个月,3年无事件生存率和总生存率分别为35.5%和49.3%。≤2个Oberlin危险因素者结局优于≥3个者。

要点

  • MTS 2008研究270例转移性横纹肌肉瘤患者3年无事件生存率为34.9%、总生存率为47.9%。
  • 汇总372例患者中位随访55.2个月,3年无事件生存率35.5%、总生存率49.3%。
  • ≤2个Oberlin危险因素者3年无事件生存率46.1% vs ≥3个者12.5%(P < .0001)。

核心结论

  • 转移性横纹肌肉瘤且伴多个Oberlin危险因素的患者结局仍然很差。
  • 因研究设计所限,无法确定强化诱导方案和/或增加维持治疗是否较历史队列带来明显改善。
  • 亟需开展采用新治疗方法的进一步研究以改善不良预后因素患者的结局。

研究设计与样本

  • MTS 2008研究纳入270例转移性横纹肌肉瘤患者,中位年龄9.6岁(范围0.07-20.8岁)。
  • 患者接受四周期异环磷酰胺、长春新碱和多柔比星(IVA)联合多柔比星、五周期IVA及12周期维持化疗(低剂量环磷酰胺和长春瑞滨)。
  • BERNIE研究将患者随机分配至同一化疗方案加或不加贝伐珠单抗。
  • 在可行时对原发肿瘤及所有转移部位给予局部治疗(手术/放疗)。
  • 汇总分析纳入372例患者,中位随访55.2个月。

主要发现

  • MTS 2008研究中位随访50.3个月,3年无事件生存率为34.9%(95% CI,29.1至40.8),总生存率为47.9%(95% CI,41.6至53.9)。
  • 汇总分析372例患者中位随访55.2个月,3年无事件生存率为35.5%(95% CI,30.4至40.6),总生存率为49.3%(95% CI,43.9至54.5)。
  • ≤2个Oberlin危险因素者3年无事件生存率为46.1%,≥3个者为12.5%(P < .0001)。
  • ≤2个Oberlin危险因素者3年总生存率为60.0%,≥3个者为26.0%(P < .0001)。
  • 诱导化疗和维持治疗似乎可耐受,但约三分之二患者在维持治疗期间需要调整剂量。

局限性

  • 因研究设计所限,无法确定强化诱导方案和/或增加维持治疗是否较历史队列带来明显改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Outcome for patients with metastatic rhabdomyosarcoma (RMS) is poor. This study presents the results of the MTS 2008 study with a pooled analysis including patients from the concurrent BERNIE study. PATIENTS AND METHODS: In MTS 2008, patients with metastatic RMS received four cycles of ifosfamide, vincristine, and actinomycin D (IVA) plus doxorubicin, five cycles of IVA, and 12 cycles of maintenance chemotherapy (low-dose cyclophosphamide and vinorelbine). The BERNIE study randomly assigned patients to the addition or not of bevacizumab to the same chemotherapy. Local therapy (surgery/radiotherapy) was given to the primary tumor and all metastatic sites when feasible. RESULTS: MTS 2008 included 270 patients (median age, 9.6 years; range, 0.07-20.8 years). With a median follow-up of 50.3 months, 3-year event-free survival (EFS) and overall survival (OS) were 34.9% (95% CI, 29.1 to 40.8) and 47.9% (95% CI, 41.6 to 53.9), respectively. In pooled analyses on 372 patients with a median follow-up of 55.2 months, 3-year EFS and OS were 35.5% (95% CI, 30.4 to 40.6) and 49.3% (95% CI, 43.9 to 54.5), respectively. Patients with ≤ 2 Oberlin risk factors (ORFs) had better outcome than those with ≥ 3 ORFs: 3-year EFS was 46.1% versus 12.5% (P < .0001) and 3-year OS 60.0% versus 26.0% (P < .0001). Induction chemotherapy and maintenance appeared tolerable; however, about two third of patients needed dose adjustments during maintenance. CONCLUSION: Outcome remains poor for patients with metastatic RMS and multiple ORFs. Because of the design of the studies, it was not possible to determine whether the intensive induction regimen and/or the addition of maintenance treatment resulted in apparent improvement of outcome compared with historical cohorts. Further studies, with novel treatment approaches are urgently needed, to improve outcome for the group of patients with adverse prognostic factors.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Schoot RA, Chisholm JC, Casanova M, et al. Metastatic Rhabdomyosarcoma: Results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study. J Clin Oncol. 2022. PMID: 35709412. doi:10.1200/JCO.21.02981

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。